The RANK ligand inhibitor denosumab is being investigated for treatment of giant cell tumor of bone, but the available data in the literature remains sparse and controversial. This study analyzes the results of combining denosumab with surgical treatment and highlights possible changes for the oncologic surgeon in daily practice.
Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series / Müller, Daniel A; Beltrami, Giovanni; Scoccianti, Guido; Campanacci, Domenico A; Franchi, Alessandro; Capanna, Rodolfo. - In: WORLD JOURNAL OF SURGICAL ONCOLOGY. - ISSN 1477-7819. - STAMPA. - 14:(2016), pp. 281-281. [10.1186/s12957-016-1034-y]
Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series
BELTRAMI, GIOVANNI;CAMPANACCI, DOMENICO ANDREA;FRANCHI, ALESSANDRO;
2016
Abstract
The RANK ligand inhibitor denosumab is being investigated for treatment of giant cell tumor of bone, but the available data in the literature remains sparse and controversial. This study analyzes the results of combining denosumab with surgical treatment and highlights possible changes for the oncologic surgeon in daily practice.
| File | Dimensione | Formato | |
|---|---|---|---|
|
12957_2016_Article_1034.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
2.69 MB
Formato
Adobe PDF
|
2.69 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
